Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Buy” from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $36.56.

XNCR has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and set a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Royal Bank of Canada increased their price objective on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Wells Fargo & Company assumed coverage on Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This trade represents a 25.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan Bruce Montgomery sold 13,301 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $27.03, for a total transaction of $359,526.03. Following the completion of the transaction, the director now owns 9,140 shares of the company’s stock, valued at $247,054.20. This represents a 59.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 136,050 shares of company stock valued at $3,277,609 over the last quarter. 5.23% of the stock is owned by insiders.

Institutional Trading of Xencor

A number of hedge funds and other institutional investors have recently made changes to their positions in XNCR. Quarry LP purchased a new position in Xencor during the 2nd quarter worth approximately $36,000. GAMMA Investing LLC grew its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares during the last quarter. KBC Group NV increased its holdings in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,213 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in Xencor in the 3rd quarter valued at $205,000. Finally, XTX Topco Ltd acquired a new stake in shares of Xencor during the second quarter worth about $196,000.

Xencor Stock Down 1.7 %

XNCR stock opened at $20.26 on Thursday. The stock has a market capitalization of $1.42 billion, a P/E ratio of -6.33 and a beta of 0.72. Xencor has a 52 week low of $15.31 and a 52 week high of $27.24. The firm has a 50-day simple moving average of $24.15 and a 200-day simple moving average of $21.01. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor’s quarterly revenue was down 81.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.40) EPS. Equities analysts forecast that Xencor will post -3.71 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.